Drug eluting stent implantation for the treatment of symptomatic myocardial bridging is associated with favorable peri-procedural results and short-term outcomes.

Abstract

Myocardial bridging is the most common congenital coronary abnormality, and is frequently found on post-mortem cardiac examination. Although often asymptomatic, clinical presentation can vary from unstable angina to sudden cardiac death. Only isolated cases of using drug eluting stents (DES) for bridging segments have been described. Our objective was to retrospectively analyze a series of patients undergoing percutaneous coronary intervention (PCI) with DES for symptomatic myocardial bridging and follow post-procedure outcomes. Results revealed favorable peri-procedural angiographic and short-term clinical results with DES implantation. Although initial data regarding DES implantation for symptomatic myocardial bridging are promising, long-term follow up, particularly related to in-stent restenosis will be important.

• Authors: Amit A Doshi, Anthony R Orsini, Ernest L Mazzaferri Jr, Wade T Schmidt, Raymond D Magorien, Charles A Bush
• Journal: International journal of cardiology (Int J Cardiol) Vol. 118 Issue 3 Pg. e87-8 (Jun 12 2007) ISSN: 1874-1754 [Electronic] Netherlands
• PMID: 17395319 (Publication Type: Letter)

Chemical References

• Paclitaxel
• Sirolimus

Topics

• Angioplasty, Balloon, Coronary (methods)
• Cohort Studies
• Coronary Angiography
• Coronary Stenosis (diagnostic imaging, therapy)
• Coronary Vessel Anomalies (diagnostic imaging, mortality, therapy)
• Drug Delivery Systems
• Female
• Heart Defects, Congenital (diagnosis, mortality, therapy)
• Humans
• Male
• Myocardial Infarction (prevention & control)
• Paclitaxel (therapeutic use)
• Prognosis
• Retrospective Studies
• Risk Assessment
• Severity of Illness Index
• Sirolimus (therapeutic use)
• Stents
• Survival Analysis
• Time Factors
• Treatment Outcome
• Vascular Patency